Fan Z, Wei X, Zhu X, Yang K, Tian L, Du Y
Sci Rep. 2024; 14(1):4477.
PMID: 38396063
PMC: 10891172.
DOI: 10.1038/s41598-024-54812-4.
Kassianides X, Bhandari S
BMC Nephrol. 2024; 25(1):54.
PMID: 38347520
PMC: 10860218.
DOI: 10.1186/s12882-023-03440-7.
Mattinzoli D, Turolo S, Ikehata M, Vettoretti S, Montini G, Agostoni C
J Clin Med. 2023; 12(18).
PMID: 37762869
PMC: 10532002.
DOI: 10.3390/jcm12185928.
Raji Y, Ajayi S, Adeoye A, Amodu O, Tayo B, Salako B
Afr Health Sci. 2022; 22(1):344-351.
PMID: 36032486
PMC: 9382529.
DOI: 10.4314/ahs.v22i1.42.
Fortova M, Hanouskova L, Valkus M, Cepova J, Prusa R, Kotaska K
Endocr Connect. 2021; 11(1).
PMID: 34860179
PMC: 8859952.
DOI: 10.1530/EC-21-0430.
The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Rysz J, Franczyk B, Rokicki R, Gluba-Brzozka A
Nutrients. 2021; 13(6).
PMID: 34208727
PMC: 8235119.
DOI: 10.3390/nu13062065.
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review.
Kassianides X, Bhandari S
Drugs Context. 2021; 10.
PMID: 33519940
PMC: 7819638.
DOI: 10.7573/dic.2020-11-3.
Caloric Intake in Renal Patients: Repercussions on Mineral Metabolism.
Vidal A, Rios R, Pineda C, Lopez I, Raya A, Aguilera-Tejero E
Nutrients. 2020; 13(1).
PMID: 33374582
PMC: 7822489.
DOI: 10.3390/nu13010018.
FGF23, Biomarker or Target?.
Rodelo-Haad C, Santamaria R, Munoz-Castaneda J, Pendon-Ruiz de Mier M, Martin-Malo A, Rodriguez M
Toxins (Basel). 2019; 11(3).
PMID: 30909513
PMC: 6468608.
DOI: 10.3390/toxins11030175.
Energy-Dense Diets and Mineral Metabolism in the Context of Chronic Kidney Disease⁻Metabolic Bone Disease (CKD-MBD).
Rodriguez M, Aguilera-Tejero E
Nutrients. 2018; 10(12).
PMID: 30513703
PMC: 6315996.
DOI: 10.3390/nu10121840.
Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C, Rodriguez-Ortiz M, Martin-Malo A, Pendon-Ruiz de Mier M, Aguera M, Munoz-Castaneda J
PLoS One. 2018; 13(8):e0201537.
PMID: 30086150
PMC: 6080760.
DOI: 10.1371/journal.pone.0201537.
Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.
Rodriguez Portillo M, Rodriguez-Ortiz M
Rev Endocr Metab Disord. 2017; 18(1):79-95.
PMID: 28378123
DOI: 10.1007/s11154-017-9421-4.
FGF23 in Acute and Chronic Illness.
Schnedl C, Fahrleitner-Pammer A, Pietschmann P, Amrein K
Dis Markers. 2015; 2015:358086.
PMID: 26491212
PMC: 4600945.
DOI: 10.1155/2015/358086.
Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.
Gonzalez-Parra E, Acena A, Lorenzo O, Tarin N, Gonzalez-Casaus M, Cristobal C
J Bone Miner Metab. 2015; 34(5):587-98.
PMID: 26298279
DOI: 10.1007/s00774-015-0706-y.
FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice.
Sun N, Guo Y, Liu W, Densmore M, Shalhoub V, Erben R
Sci Rep. 2015; 5:8304.
PMID: 25665715
PMC: 4322353.
DOI: 10.1038/srep08304.
Recent developments in metabolic bone diseases: a gnathic perspective.
Raubenheimer E, Noffke C, Hendrik H
Head Neck Pathol. 2014; 8(4):475-81.
PMID: 25409845
PMC: 4245412.
DOI: 10.1007/s12105-014-0580-2.
The Roles of Fibroblast Growth Factor (FGF)-23, α-Klotho and Furin Protease in Calcium and Phosphate Homeostasis : A Mini-Review.
Mattoo R
Indian J Clin Biochem. 2014; 29(1):8-12.
PMID: 24478543
PMC: 3903929.
DOI: 10.1007/s12291-013-0324-1.
FGF23 associated bone diseases.
Liao E
Front Med. 2013; 7(1):65-80.
PMID: 23471660
DOI: 10.1007/s11684-013-0254-6.
